For the prevention of diseases caused by Haemophilus influenzae type b (Hib), the Hiberix vaccination is carried out. The vaccine begins to protect the body a month after it, when antibodies are produced. This occurs in 95-100% of cases. After revaccination, antibodies appear in 100% of children. It should be known to those who use the Hiberix vaccine: the vaccine does not protect against bacterial meningitis and from diseases caused by other types of Haemophilus influenzae. There should be an interval of up to two months between injections. The first vaccination is carried out from six weeks, and at two years a second vaccination is carried out.
Hiberix. Vaccine information
The drug can be administered in the same syringe with a vaccine against pertussis, poliomyelitis, diphtheria, tetanus, measles, rubella and mumps. The drug is administered intramuscularly. After vaccination, side effects may occur. Basically, these are local reactions in the form of a small spontaneously disappearing hyperemia, soreness at the injection site and mild swelling. Systemic reactions manifest as restlessness, fever, decreased appetite, diarrhea, and nausea. As a rule, they are insignificant and do not require any treatment.
In exceptional cases, allergic reactions, including anaphylactic shock, are possible. There are negative reviews about the Hiberix vaccine. Usually they are left by parents whose children were vaccinated during the illness. In this case, complications may develop. The vaccine is applied until the age of five. Vaccinated patients should be monitored by a doctor for half an hour, since an anaphylactic reaction is possible , but this happens in isolated cases.
Release form and composition
The vaccine used to vaccinate is of good quality. Hiberix is a drug manufactured by the Belgian company GlaxoSmithKline. The product contains one dose (10 μg) of a purified Hib capsule polysaccharide (PRP) conjugated to tetanus toxoid (Haemophilus influenzae type B). The drug is available in ampoules or vials in the form of a lyophilisate, from which a solution is prepared for subcutaneous and intramuscular administration.
Vaccination schedule
The start of vaccination for the prevention of hemophilic b-infection is provided from the age of three months. The course includes three vaccinations at intervals of one, one and a half or two months between doses. In the second year of the child's life, re-vaccination with the Hiberix drug should be carried out. Vaccination of children at six months of age is carried out in two stages with an interval of one month.
Benefits and contraindications
Vaccination is not carried out if the child has acute infectious diseases that are accompanied by fever. An individual reaction to the components of the Hiberix vaccine is possible. If hypersensitivity reactions have been observed after previous injections of the drug, re-vaccination is not carried out.
If we talk about the benefits, it is worth noting that the "Hiberix" preparation does not contain live microorganisms. Thanks to vaccination, antibodies are produced that help prevent the most serious in terms of HIB meningitis and other forms of infection. The Hiberix vaccine is relatively safe - the vaccine is fairly easy to tolerate. Side effects are mostly mild and short-lived.